Press release
HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Shows Strong Momentum as 5+ Pharma Companies in the Race | DelveInsight
Curious about the latest updates in the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline? @ https://www.delveinsight.com/sample-request/hpv-recurrentmetastatic-head-and-neck-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/hpv-recurrentmetastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report
* On May 22, 2026- BioNTech SE initiated a Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) greater than or equal to 1.
* On May 06, 2026- Regeneron Pharmaceuticals conducted a phase II study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "study drugs" in this form.
* On April 09, 2026- GlaxoSmithKline conducted a phase 2 study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
* On April 06, 2026- PDS Biotechnology Corp . initiated a Phase 3 study that is randomized 1:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherapy as first-line treatment in patients with unresectable recurrent or metastatic HPV16-positive HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) greater than or equal to 1.
* On April 06, 2026- AVEO Pharmaceuticals Inc . announced a phase 3 study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
* DelveInsight's HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for HPV+ Recurrent/Metastatic Head and Neck Cancer treatment.
* The leading HPV+ Recurrent/Metastatic Head and Neck Cancer Companies such as BioNTech, Cue Biopharma, Hookipa Pharma and others.
* Promising HPV+ Recurrent/Metastatic Head and Neck Cancer Therapies such as PF-00299804, GSK1363089 (foretinib), Pemetrexed, Cetuximab, Cisplatin, Carboplatin, RiMO-301 and others.
Want to know which companies are leading innovation in HPV+ Recurrent/Metastatic Head and Neck Cancer? @ HPV+ Recurrent/Metastatic Head and Neck Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hpv-recurrentmetastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report also highlights the unmet needs with respect to the HPV+ Recurrent/Metastatic Head and Neck Cancer.
HPV+ Recurrent/Metastatic Head and Neck Cancer Overview
Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box). These cancers are referred to as squamous cell carcinomas of the head and neck. Head and neck cancers can also begin in the salivary glands, sinuses, or muscles or nerves in the head and neck, but these types of cancer are much less common than squamous cell carcinomas. Head and neck cancer symptoms may include a lump in the neck or a sore in the mouth or the throat that does not heal and may be painful, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice.
HPV+ Recurrent/Metastatic Head and Neck Cancer Emerging Drugs Profile
* CUE 101: Cue Biopharma
Cue Biopharma is advancing a pipeline of targeted interleukin 2 (IL-2)-based immunotherapies for multiple types of cancers with high unmet needs. The CUE-100 series of biologics have the potential to improve efficacy and reduce the severe toxicities associated with non-specific IL-2 cancer immunotherapies. CUE-101, has already demonstrated clinical activity and favorable tolerability as a monotherapy in a Phase 1 trial in patients with human papilloma virus (HPV16+) recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
* BNT 113: BioNTech
BNT113 is an mRNA cancer vaccine encoding two oncoproteins, E6 and E7,that are frequently found in HPV16+ solid cancers aiming to trigger a strong and precise immune response in patients with HPV16+ head and neck squamous cell carcinoma (HNSCC). BNT113 is currently being evaluated in a Phase 2 study, AHEAD-MERIT, in combination with Merck's pembrolizumab, a PD-1 inhibitor, vs. pembrolizumab alone in patients with unresectable recurrent or metastatic HPV+ PD-1+ HNSCCs. Results from an investigator-initiated Phase 1/2 basket trial, HARE-40, in patients with HPV16+ cancers showed that BNT113 treatment induces potent, antigen-specific T cell responses.
If you're tracking ongoing HPV+ Recurrent/Metastatic Head and Neck Cancer Clinical trials @ HPV+ Recurrent/Metastatic Head and Neck Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/hpv-recurrentmetastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of HPV+ Recurrent/Metastatic Head and Neck Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HPV+ Recurrent/Metastatic Head and Neck Cancer Treatment.
* HPV+ Recurrent/Metastatic Head and Neck Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* HPV+ Recurrent/Metastatic Head and Neck Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HPV+ Recurrent/Metastatic Head and Neck Cancer market.
HPV+ Recurrent/Metastatic Head and Neck Cancer Companies
BioNTech, Cue Biopharma, Hookipa Pharma and others.
HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
HPV+ Recurrent/Metastatic Head and Neck Cancer Products have been categorized under various Molecule types such as,
* Oligonucleotide
* Peptide
* Small molecule
From emerging drug candidates to competitive intelligence, the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report @ HPV+ Recurrent/Metastatic Head and Neck Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hpv-recurrentmetastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report
* Coverage- Global
* HPV+ Recurrent/Metastatic Head and Neck Cancer Companies- BioNTech, Cue Biopharma, Hookipa Pharma and others.
* HPV+ Recurrent/Metastatic Head and Neck Cancer Therapies- PF-00299804, GSK1363089 (foretinib), Pemetrexed, Cetuximab, Cisplatin, Carboplatin, RiMO-301 and others.
* HPV+ Recurrent/Metastatic Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* HPV+ Recurrent/Metastatic Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discover what's next for the HPV+ Recurrent/Metastatic Head and Neck Cancer Treatment landscape in this detailed analysis @ HPV+ Recurrent/Metastatic Head and Neck Cancer Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/hpv-recurrentmetastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* HPV+ Recurrent/Metastatic Head and Neck Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* HPV+ Recurrent/Metastatic Head and Neck Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Mid Stage Products (Phase II)
* Early Stage Products (Phase I)
* BNT 113: BioNTech
* Preclinical and Discovery Stage Products
* Inactive Products
* HPV+ Recurrent/Metastatic Head and Neck Cancer Key Companies
* HPV+ Recurrent/Metastatic Head and Neck Cancer Key Products
* HPV+ Recurrent/Metastatic Head and Neck Cancer- Unmet Needs
* HPV+ Recurrent/Metastatic Head and Neck Cancer- Market Drivers and Barriers
* HPV+ Recurrent/Metastatic Head and Neck Cancer- Future Perspectives and Conclusion
* HPV+ Recurrent/Metastatic Head and Neck Cancer Analyst Views
* HPV+ Recurrent/Metastatic Head and Neck Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hpv-recurrentmetastatic-head-and-neck-cancer-pipeline-shows-strong-momentum-as-5-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hpv-recurrentmetastatic-head-and-neck-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Shows Strong Momentum as 5+ Pharma Companies in the Race | DelveInsight here
News-ID: 4552053 • Views: …
More Releases from ABNewswire
Stand Out from the Crowd: 1228Teez Delivers One-of-a-Kind Graphic Tees Designed …
Woman-owned apparel brand 1228Teez is on a mission to help customers express themselves through unique, high-quality graphic tees that combine humor, originality, and inclusive sizing. The brand's growing collection offers designs that cannot be found through mainstream retailers.
The graphic tee has long been one of the most democratic pieces in fashion. It requires no styling expertise, works in nearly any casual setting, and offers a blank canvas for personal expression.…
Missed Calls Mean Lost Bookings as TransportBPO Enters the Market With Round-the …
With dispatcher shortages intensifying and customer patience shrinking, TransportBPO has launched a dedicated outsourcing service that gives ground transportation operators in four countries access to 24/7 trained dispatch and call coverage. The company targets the growing gap between what small and mid-size fleets can afford in-house and what modern passengers demand.
The economics of running a small or mid-size ground transportation business have shifted dramatically in recent years. Fuel costs fluctuate,…
From Military Service to Master Roasting: How Eager Beaver Roasters LLC Turned a …
Eager Beaver Roasters LLC channels the founders' veteran discipline and lifelong coffee passion into a growing business that sources beans from premier farms worldwide. The San Diego-based company offers expertly roasted coffee, fine teas, and branded apparel to a devoted customer base that shares their obsession with the perfect cup.
Behind every great coffee brand is a story, and the one behind Eager Beaver Roasters LLC is rooted in service, sacrifice,…
New Memoir New Life at Ninety Celebrates a Lifetime of God's Grace, Mercy, and F …
Image: http://www.abnewswire.com/pressreleases/wp-content/uploads/2026/07/2026
A powerful spiritual autobiography from Rev. Daniel W. Reid reminds readers that God's love never gives up, and that it is never too late for a new beginning.
What does a lifetime of God's faithfulness look like?
In New Life at Ninety , Rev. Daniel W. Reid opens the pages of his life, not to celebrate his own accomplishments, but to bear witness to something far greater: the steadfast love, mercy,…
More Releases for Head
Head to Head in 2026: The Best AI for Consulting Presentations
How the best AI for consulting presentations stacks up against the general-purpose tools buyers still shortlist.
Buyers weighing slide software in 2026 face a familiar fork in the road, choosing between broad general-purpose assistants and something built for the specific demands of client-facing work. That decision is why more teams now put the best ai for consulting presentations conversation around Oria [https://www.oria.one], a purpose-built engine that treats editable, consulting-grade output as…
Phillips-head pan head machine screw - Specifications and Industry Applications
A cross-head machine screw typically refers to a machine screw with a Phillips drive (also known as a cross-recess or Type I recess). Machine screws are precision-Engineered Fasteners [https://www.bsf-cn.com/engineered-fasteners/] with uniform threads designed to mate with pre-tapped holes or nuts, offering a secure and repeatable assembly.
Key Characteristics
Drive Type: The Phillips cross-shaped indentation in the head provides four points of contact for the screwdriver. This design allows for a self-centering action…
Green Dot Sign® Going Head-to-Head with Traditional Plastic ADA Signs
After the success of their groundbreaking sustainable ADA compliant interior signs, Green Dot Sign® is now offering a more affordable and adaptable option than ever before: Low profile office signs.
Nussbaum started considering environmentally-friendly manufacturing methods and products while working at his prior sign company. The idea to create signage from a wood base and non-toxic 3D printed material for lettering, braille, and pictograms was sparked by a braille sign with…
China and India are growing head to head in Companion Diagnostic market
“Asia-Pacific Companion Diagnostics Market" research report, published by Market Data Forecast estimates that the market is growing with a CAGR of 27.91% to reach USD 2.17 billion by 2021, from USD 0.63 billion in 2016, which amounts to a cumulative growth of USD 1.54 billion.
A companion diagnostics device is a medical device that provides information which is necessary for drug safety and effectives or any other biological product. This helps…
dinCloud Earns Top Marks in Head-to-Head Comparison
The #1 Brand in Hosted Virtual Desktops
LOS ANGELES, CA – June 19, 2012 – dinCloud, a cloud transformation company and provider of hosted virtual desktops, has come out on top as the leading provider of DaaS (Desktop as a Service) in a head-to-head comparison of five market leaders by ExtremeLabs. dinCloud’s solution received the groupings highest marks for the solution’s good control, as well as fast response, and was the…
KnowledgetoAction Departments Go Head to Head in a Bowling Competition
London, UK ( ) October 25, 2010 - Employees of KnowledgetoAction (http://knowledgeandaction.co.uk) have been going head to head against each other in a series of team building competitions that began on September 1, 2010. Knowledge to Action believes strongly in team building and this event showcased their desire for excellent team cooperation and communication between departments, allowing for more cohesiveness within Knowledge to Action.
Most recently, each of the KnowledgetoAction…
